CURRICULUM VITAE

Personal Information

Name: Tamás Bakos

Home address: 9230 Camborne, San Antonio, TX 78250Tel.: (210)-315-7105 Email: bakost@sbcglobal.net

Education

1987-1991 Graduate Student of the Hungarian Academy of Sciences, Ph. D.

1982-1987 University of Szeged, M. Sc.

Work Experience

2005-2016 Principal Research Scientist, Project Leader, Oncovista Inc., San Antonio, TX

1993-2005 Senior Research Scientist, Lipitek International Inc., San Antonio, TX

1991-1995 Associate Professor, Department of Organic Chemistry, University of Szeged, Hungary

1989-1991 Research Associate (Predoctoral Fellow), Institut de Chimie des Substances Naturelles, Centre National de la Recherche Scientifique, Gif-sur-Yvette, France

1987-1989 Research Assistant, Department of Organic Chemistry,University of Szeged, Hungary

Major Accomplishments

-Good Manufacturing Practice production of the following clinical trial materials:

Crisnatol (polyaromatic)Irofulven (terpenoid),Combretastatin A-4 (stilbenoid),Camptothecin (quinoline alkaloid) Cordycepin (nucleoside), L-117 (dinucleotide), Ro-23-7553 (vitamin D)Squalamine (steroid polyamine).

-Over the last decade, L-117 anticancer dinucleotide was designed and developed under my leadership. A 14-step synthesis was optimized and scaled-up to produce under cGMP conditions multiple kilograms of the target compound. After successful animal studies and IND preparation, L-117 has been approved by the FDA to enter Phase I human trials.

Relevant Experience

-In-depth knowledge of academic and industrial research of new anticancer drugs, process optimization and method development, scale-up of multi-step synthetic processes, pilot scale syntheses.

-Familiarity with the large scale synthesis and purification of polyaromatics, terpenoids, steroids, nucleosides, nucleotides and other natural products as antineoplastic agents for clinical trials.

-Application of spectroscopic methods (IR, UV, MS, NMR), analytical and computer skills.-Experience in the regulatory compliance activities related to drug development and clinical trials.

-Proficiency in preparing Standard Operating Procedures and Batch Records.

Scope of Research

-Synthetic organic chemistry, medicinal chemistry, pharmaceutical chemistry; chemical modification of natural products, isolation and purification of biomolecules.

-Proven track record in steroid chemistry, carbohydrate chemistry, nucleic acid chemistry, lipid chemistry, polyamine chemistry.

-Strong background in the design and development of new synthetic carbohydrates, nucleosides, nucleotides, antibiotics, terpenoids and steroids for therapeutic purposes.

-Steroids, investigation of reaction mechanism on the steroid skeleton, synthesis of ligands for receptor determinations, synthesis of serum cholesterol lowering derivatives, synthesis of anticancer steroidal polyamines (squalamines), synthesis of vitamin D3 derivatives as antileukemic agents.

-Design and synthesis of L-nucleosides and L-nucleotides as antiparasitic and anticancer agents.

-Background in anti-mitotic drugs: taxanes, colchicines and combretastatins.

-Knowledge in the design and synthesis of fluorescent probes.

-Experience in liposomes and encapsulation of biomolecules.

-Structure-activity studies of 16-membered macrolide antibiotics, terpenoids, steroids, nucleosides and nucleotides, taxanes and colchicine derivatives.

Awards and Honors

Postgraduate Fellowship of the Hungarian Academy of Sciences, Szeged, Hungary, 1987-1991

Fellowship of the French Ministry of Foreign Affairs, Paris, France, 1989-1990

Fellowship of the Centre National de la Recherche Scientifique, Gif-sur-Yvette, France, 1990-1991

Knowledge of Languages

Hungarian: nativeEnglish: fluentFrench: fluent

Selected Publications, Presentations and Patents

1. Bakos T, Vincze I. Direct, high-yield transformation of tetrahydropyranyl ethers to acetates. Synth Comm 1989; 19:523-528.

2. Bakos T, Vincze I. A new route to 16-methylene-17-ketosteroids. Synth Comm 1992; 22:1377-1383.

3. Bakos T, Horváth J, Vincze I. Steroids 47. A facile synthesis of 3-hydroxy-5-cholest-8(14)-en-15-one. Chem Phys Lipids 1992; 63:23-26.

4. Lőkös M, Bakos T, Vincze I. Steroids 48. Synthesis of 16-ethyl-21-hydroxy-19-norpregna-4-ene-3,20-dione from 17-substituted 3-methoxyestradiols. Steroids 1993; 58:220-224.

5. Vincze I, Lőkös M, Bakos T, Dancsi A, Mák M. Steroids 49. Investigations on the dehydratation of 17-ethynyl-17-hydroxysteroids. Steroids 1993; 58:220-224.

6. Bakos T, Lőkös M, Vincze I, Volford J. Steroids 51. An improved synthesis of ORG 2058 and the synthesis of [3H]ORG 2058. Steroids 1993; 58:115-118.

7. Bobillot S, Bakos T, Sarda P, Thang TT, Ming L, Olesker A, Lukacs G. Chemical modification of tylosin. J of Antibiotics 1995; 48:667-670.

8. Weis AL, Bakos T, Goodhue CT. L-Erythrosyl Nucleosides. US Patent # 5,672,594. Issued Sep. 30, 1997.

9. Weis AL, Bakos T, Alferiev I, Zhang X, Shao B, Kinney WA. Synthesis of an azido spermidine equivalent. Tetrahedron Lett 1999; 40:4863-4864.

10. Kinney WA, Shao B, Zhang X, Weis AL, Bakos T, Alferiev I. Synthesis of Squalamine via Novel

Spermidine Equivalent. 218th American Chemical Society National Meeting, New Orleans, LA, August 22-26, 1999.

11. Dolinnaya N, Amosova O, Bakos T, Weis AL, Fresco JL. Fluorescent TISH Probes for Cancer-Relevant Sequences. IMAT NCI Meeting, Washington, D.C., June 2001.

12. Gero AM, Dunn CG, Brown DM, Pulenthiran K, Gorovits EL, Bakos T, Weis AL. New malaria chemotherapy developed by utilization of a unique parasite transport system. Curr Pharm Des 2003; 9:867-877.

13. Lowell W, Wick M, Levenson C, Marty J, Bakos T, Gorovits E, Pulentiran K, Takimoto C, Weis A. Preclinical evaluation of the nucleoside dimer analog L-117 in the HT-29 human colorectal tumor xenograft model. Clin Cancer Res 2005; 11:9017S.

14. Huzil JH, Winter P, Johnson L, Weis AL, Bakos T, Banerjee A, Luduena RF, Damaraju S, Tuszynski JA. Computational Design and Biological Testing of Highly Cytotoxic Colchicine Ring A Modifications. Chem Biol Drug Des 2010; 75:541-550.

15. Yeh LCC, Banerjee A, Prasad V, Tuszynski JA, Weis AL, Bakos T, Yeh IT, Luduena RF, Lee JC. Effect of CH-35, a novel anti-tumor colchicine analogue, on breast cancer cells overexpressing the βIII isotype of tubulin. Inv New Drugs 2016; 34:129-137.